Briefing
Minimal residual disease guided maintenance with belantamab mafodotin and lenalidomide after transplant in newly diagnosed myeloma
Phase 2 trial of MRD-guided post-transplant maintenance. The registry primary outcome is conversion from MRD-positive to MRD-negative complete response. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting